E.F. Nash

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

Harry Heijerman, Edward F. McKone, D.G. Downey et al. · The Lancet · 2019 · 1.4K citations · Full text

Life Sciences, Genetics, Pharmacology +14

Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium

Josephine M. Bryant, Dorothy Grogono, Daniela Rodriguez-Rincon et al. · Science · 2016 · 588 citations

Life Sciences, Infectious Diseases, Microbiology +17

A next-generation liquid xenon observatory for dark matter and neutrino physics

J. Aalbers, Shehu AbdusSalam, K. Abe et al. · Journal of Physics G Nuclear and Particle Physics · 2022 · 155 citations · Full text

Natural Sciences, Physics, Cosmology +15

<i>Pseudomonas aeruginosa</i>quorum sensing molecules correlate with clinical status in cystic fibrosis

H. Barr, Nigel Halliday, Miguel Cámara et al. · European Respiratory Journal · 2015 · 105 citations · Full text

Medicine, Infectious Diseases, Pharmacology +16

Characterising burden of treatment in cystic fibrosis to identify priority areas for clinical trials

Gwyneth Davies, Nicola J. Rowbotham, Sherie Smith et al. · Journal of Cystic Fibrosis · 2019 · 104 citations · Full text

Pharmacy, Molecular Medicine, Pharmacotherapy +13